Trademark Rejections: Pandemic Edition
Disasters and protests tend to bring out opportunists who attempt to capitalize on a popular term or rallying cry. This often ends in trademark applicants burning money on trademark applications that will likely end in both rejection by the United States Patent and...
Current Blockchain Issues in Patent Law
Blockchain Patentability Background Since blockchain technology was created in 2008 by the founder of Bitcoin, Satoshi Nakamoto, it has been difficult for the patent community to understand how to best handle blockchain innovations. The algorithms and processes...
Foreign-domiciled Trademark Applicants and Registrants must be represented by U.S. Counsel
By: Adam Baechler Effective August 3, 2019, the United States Patent and Trademark Office (USPTO) enacted a new rule requiring all foreign trademark applicants and registrants be represented by a U.S. licensed attorney.[1] Foreign trademark applicants and registrants...
Federal Appeals Court Awards Patent Rights in CRISPR Gene Editing Case to Harvard and Broad Institute Team, Likely Signaling the End to a 4-Year Protracted Patent Dispute
On September 10, 2018, the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a long-awaited decision in a patent interference case pitting researchers from the Massachusetts Institute of Technology (MIT) and Harvard University’s Broad Institute against...
Novel FDA Early Feasibility Studies for Medical Devices: FDA Highlights Success From Pilot
Congratulations to our client BiO2 Medical, Inc.!!! In a paper published in the last week, two officials from the US Food and Drug Administration (FDA) say that the agency's early feasibility study (EFS) program helped optimize the development of a new type of...
FeSSIF/FaSSIF Dissolution: If you Understand What is Written Above You Should Read this Article
FeSSIF/FaSSIF Dissolution: If you Understand What is Written Above You Should Read this Article A part of any complete study for a pre-clinical candidate (PCC) pharmaceutical compound is a dissolution study in Fed and Fasted Simulated Stomach and Intestinal Fluids...
Phase III Biosimilar Clinical Trial & Infringement Threat does not Create Justiciable Case or Controversy: Biosimilars will require the Patent Dance
Phase III Biosimilar Clinical Trial & Infringement Threat does not Create Justiciable Case or Controversy: Biosimilars will require the Patent Dance In Sandoz Inc. v. Amgen Inc., the Federal Circuit upheld the district court decision dismissing Sandoz’s...
USPTO Issues New & Revised Guidance on Patent Eligibility Under 35 USC § 101
USPTO Issues New & Revised Guidance on Patent Eligibility Under 35 USC § 101 The United States Patent and Trademark Office (USPTO) has issued revised guidance to its examiners relating to determination of patent eligibility under 35 U.S.C. §101. This “Interim...
No Legal Advice Intended: This website includes information about legal issues and legal developments. Such materials are for informational purposes only and may not reflect the most current legal developments. These informational materials are not intended, and should not be taken, as legal advice on any particular set of facts or circumstances. You should contact an attorney for advice on specific legal problems.
